Titre :

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.

Auteur(s) :

Gall, G. L. [Auteur]
Cherifi, F. [Auteur]
Divoux, J. [Auteur]
Florent, R. [Auteur]
Christy, F. [Auteur]
Leconte, A. [Auteur]
San, C. [Auteur]
Devillers, A. [Auteur]
Desmartin, G. [Auteur]
Lecouflet, L. [Auteur]
Clarisse, B. [Auteur]
Ballesta, S. [Auteur]
Thorel, L. [Auteur]
Dubois, B. [Auteur]
Harter, V. [Auteur]
Rousseau, N. [Auteur]
Gaichies, L. [Auteur]
Martin-Françoise, S. [Auteur]
Le Brun, J. F. [Auteur]
Dolivet, E. [Auteur]
Rouzier, R. [Auteur]
Jeanne, C. [Auteur]
Blanc-Fournier, C. [Auteur]
Figeac, Martin [Auteur]
Plateformes Lilloises en Biologie et Santé (PLBS) - UAR 2014 - US 41
Leman, R. [Auteur]
Castera, L. [Auteur]
Poulain, L. [Auteur]
Weiswald, Louis-Bastien [Auteur]
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers [ANTICIPE]
Joly, Florence [Auteur]
Service de recherche clinique [Centre François Baclesse]

Titre de la revue :

BMC Cancer

Nom court de la revue :

BMC Cancer

Numéro :

25

Pagination :

244

Éditeur :

BMC

Date de publication :

2025-02-22

ISSN :

1471-2407

Mot(s)-clé(s) en anglais :

Endometrial cancer
Patient-derived tumor organoids
Predictive functional assays
Homologous recombination deficiency
PARP inhibitors

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background Combination of chemotherapy and immunotherapy is the current standard of care for advanced endometrial cancer. However, survival outcome remains poor, highlighting the urgent need for new treatments and reliable ...
Lire la suite >Background Combination of chemotherapy and immunotherapy is the current standard of care for advanced endometrial cancer. However, survival outcome remains poor, highlighting the urgent need for new treatments and reliable tools to identify patients who will benefit from them. Patient-Derived Tumor Organoids (PDTO) are three-dimensional structures established from patient tumors, and are closely mimicking the features of the tumor of origin. Moreover, more and more evidences show that PTDOs hold promises as predictive tools for the response to treatment of patients. Method The PENDOR study is a monocentric observational study designed to assess the feasibility of generating and testing PDTOs derived from endometrial cancer for evaluating treatment sensitivity. PDTOS will be established from surgical specimens not required for anatomopathological diagnosis. Tumor cells will be dissociated, embedded in extracellular matrix, and cultured in a medium supplemented with growth factors and signaling pathways inhibitors. Molecular and histological analyses will be conducted to validate the resemblance of PDTO to the original tumor. Response of PDTO to conventional chemotherapy and PARP inhibitors will be evaluated and compared to clinical response and to the results of an academic HRD test Genomic Instability Scar (GIScar), respectively, to assess their predictive value. Discussion This pilot study aims to validate the feasibility to develop PDTOs from endometrial cancer from patients who will undergo surgical resection. We aim to provide a proof of concept regarding the predictive value of these models for their potential application into routine clinical practice as part of precision medicine. This approach could therefore facilitate the identification of patients who could benefit from PARP inhibitors.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille

Collections :

• Plateformes Lilloises en Biologie et Santé (PLBS) - UAR 2014 - US 41

Date de dépôt :

2025-03-11T22:02:50Z
2025-03-19T10:29:27Z